# US 2019/0056411 A1 · Systemic immune activation and biomarkers of nonceliac wheat/gluten sensitivity

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0056411 A1
- Document ID: US20190056411A1
- Status: Published application
- Kind: A1
- Application number: 16/079,321
- Filed: 2017-02-24
- Published: 2019-02-21
- Earliest claimed: 2016-02-25
- Assignees: The Trustees of Columbia University in the City of New York
- Applicants: The Trustees of Columbia University In the City of New York
- Inventors: Armin Alaedini
- Web page: https://patentgrep.com/patent/US20190056411A1

## CPC

- G01N 33/6893: {related to diseases not provided for elsewhere}
- C07K 16/16: against material from plants
- G01N 33/53: Immunoassay; Biospecific binding assay; Materials therefor
- G01N 33/564: for pre-existing immune complex or autoimmune disease {, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9}
- G01N 33/92: involving lipids, e.g. cholesterol {, lipoproteins, or their receptors (steroid hormones G01N33/743)}
- G01N 2333/4703: Regulators; Modulating activity
- G01N 2333/70596: Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
- G01N 2800/02: Nutritional disorders
- G01N 2800/24: Immunology or allergic disorders
- G01N 2800/52: Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The present invention provides a method of using increased levels of one or more biomarkers to identify subjects having non-celiac gluten sensitivity or non-celiac wheat sensitivity. The identification would aid the physician or health professional to determine a specific treatment for the patient, for example, a diet that eliminates wheat, rye, and/or barley. In one embodiment, the biomarkers are one or more of soluble CD 14 (sCD14), lipopolysaccharide-binding protein (LBP), anti-lipopolysaccharide antibodies, anti-flagellin antibodies, anti-gliadin antibodies, and intestinal fatty acid-binding protein (FABP2). The present invention also provides a method of using the same markers to monitor the response to treatment for non-celiac wheat sensitivity in a subject.

## Claims

### Claim at position 1

1-8. (canceled)

### Claim 9

A method of treating a subject having non-celiac wheat sensitivity, comprising the steps of:
i. determining blood levels of one or more markers in said subject, said markers are selected from the group consisting of soluble CD 14, lipopolysaccharide-binding protein (LBP), anti-lipopolysaccharide antibodies, anti-flagellin antibodies, anti-gliadin antibodies, and intestinal fatty acid-binding protein (FABP2), wherein increased levels of said markers in said subject as compared to control levels indicate said subject has non-celiac wheat sensitivity; and
ii. treating the subject identified in (i) with a diet free of one or more of wheat, rye and barley.

### Claim 10 (depends on 9)

The method of claim 9, wherein said control levels are derived from healthy subjects or subjects having celiac disease.

### Claim 11 (depends on 9)

The method of claim 9, wherein levels of said markers are determined in serum or plasma.

### Claim 12 (depends on 9)

The method of claim 9, wherein said anti-lipopolysaccharide antibodies are IgM antibodies.

### Claim 13 (depends on 9)

The method of claim 9, wherein said anti-flagellin antibodies are one or both of IgM antibodies and IgG antibodies.

### Claim 14 (depends on 9)

The method of claim 9, wherein said anti-gliadin antibodies are one or more of IgA, IgM and IgG antibodies.

### Claim 15

A method of monitoring response to a treatment for non-celiac wheat sensitivity in a subject, comprising the step of determining blood levels of one or more markers in said subject before and after said treatment, said markers are selected from the group consisting of soluble CD 14 (sCD14), lipopolysaccharide-binding protein (LBP), anti-lipopolysaccharide antibodies, anti-flagellin antibodies, anti-gliadin antibodies, and intestinal fatty acid-binding protein (FABP2), wherein decreased levels of said markers in said subject after said treatment indicate that said subject has responded to said treatment, otherwise the subject has not responded to the treatment.

### Claim 16 (depends on 15)

The method of claim 15, wherein levels of said markers are determined in serum or plasma.

### Claim 17 (depends on 15)

The method of claim 15, wherein said anti-lipopoly saccharide antibodies are IgM antibodies.

### Claim 18 (depends on 15)

The method of claim 15, wherein said anti-flagellin antibodies are one or both of IgM antibodies and IgG antibodies.

### Claim 19 (depends on 15)

The method of claim 15, wherein the anti-gliadin antibodies are one or more of IgG, IgA, and IgM antibodies.

### Claim 20 (depends on 15)

The method of claim 15, wherein the treatment comprises a diet free of one or more of wheat, rye and barley.

### Claim 21

A method of determining a course of treatment for non-celiac wheat sensitivity in a subject, comprising the step of determining blood levels of one or more markers in said subject before and after said treatment, said markers are selected from the group consisting of soluble CD 14 (sCD14), lipopolysaccharide-binding protein (LBP), anti-lipopolysaccharide antibodies, anti-flagellin antibodies, anti-gliadin antibodies, and intestinal fatty acid-binding protein (FABP2),
wherein decreased levels of said markers in said subject after said treatment indicate said subject should continue to be treated with said treatment,
wherein when the levels of the markers do not decrease after said treatment, said subject should be treated with an alternative treatment.

### Claim 22 (depends on 21)

The method of claim 21, wherein levels of said markers are determined in serum or plasma.

### Claim 23 (depends on 21)

The method of claim 21, wherein said anti-lipopolysaccharide antibodies are IgM antibodies.

### Claim 24 (depends on 21)

The method of claim 21, wherein said anti-flagellin antibodies are one or both of IgM antibodies and IgG antibodies.

### Claim 25 (depends on 21)

The method of claim 21, wherein the anti-gliadin antibodies are one or more of IgG, IgA, and IgM antibodies.

### Claim 26 (depends on 21)

The method of claim 21, wherein the treatment comprises a diet free of one or more wheat, rye and barley.

### Claim 27

A kit that aids in diagnosis of non-celiac wheat sensitivity in a subject, comprising reagents that detect the presence of one or more markers in a sample from said subject, said markers are selected from the group consisting of soluble CD 14 (sCD14), lipopolysaccharide-binding protein (LBP), anti-lipopolysaccharide antibodies, anti-flagellin antibodies, anti-gliadin antibodies, and intestinal fatty acid-binding protein (FABP2).

### Claim 28

(canceled)

### Claim 29 (depends on 27)

The kit of claim 27, wherein said anti-lipopolysaccharide antibodies are IgM antibodies and said anti-flagellin antibodies are one or both of IgM antibodies and IgG antibodies.
